The labs came back and someone said the words: your results are within normal range. That sentence ends more hormone optimization journeys before they begin than any other single event in medicine — and for a significant share of the patients who hear it, it is clinically incomplete. Not because the numbers were falsified, but because the wrong numbers were ordered, or the reference range being used was built on a population that does not resemble the patient sitting in the chair, or both.
GoodLife Health was built for the patient who received that sentence and did not accept it. This is the clinically honest guide to hormone optimization programs in 2026 — for men and women — covering what the labs actually tell you, what a complete protocol looks like, and why your provider's incentive structure determines your outcome.
- Hormone optimization is the clinical management of a chronic, often progressive condition — hormonal dysregulation — that affects energy, body composition, cognition, mood, sexual function, bone density, and cardiovascular health in men and women alike.
- The most common failure mode is treating a single hormone in isolation. Testosterone without thyroid. Estrogen without progesterone. Thyroid without adrenal context. A single-hormone protocol applied to a multi-hormonal problem produces partial results at best.
- TSH alone is not a thyroid panel — for men or women. A complete assessment requires free T3, free T4, reverse T3, and thyroid antibodies at minimum.
- Low testosterone is not a men's issue. It is a human issue. Women with low testosterone report loss of drive, flat libido, cognitive fog, and loss of lean mass — and are diagnosed far less frequently because the reference ranges were built on male physiology.
- The hormone-weight connection is direct and measurable. A patient with undertreated hypothyroidism, low testosterone, or estrogen dominance will not lose meaningful weight on GLP-1 regardless of dose.
- GoodLife Health Tier 1 at $299 per month covers the complete protocol for both men and women: comprehensive baseline panel, protocol design by Kristin Makinajyan, DNP, FNP-BC, ongoing titration, and unlimited clinician messaging. Medication is separate at your pharmacy. GoodLife takes no margin on any prescription.
- The correct question to ask any hormone provider is not "what do you prescribe?" It is "what do you measure, how often, and what is your titration logic when the first protocol does not work?"
The Appointment You Should Have Had
You went in with a list. Fatigue that sleep does not fix. Weight that does not move despite doing everything right. A libido that disappeared months ago. Cognitive fog that you have started calling your new normal. You mentioned all of it. The labs came back and someone said the words: your results are within normal range.
That experience is not unique to you. It is the defining experience of primary care in the United States in 2026. For patients navigating hormonal symptoms, metabolic dysfunction, or the slow accumulation of conditions that do not yet have a clean diagnostic code, an eleven-minute appointment and a TSH-only panel are not enough. They have never been enough.
What Hormone Optimization Actually Is
Hormone optimization is the clinical practice of assessing, diagnosing, and treating suboptimal hormone levels to restore physiological function. It is not about achieving supraphysiologic levels. It is not anti-aging marketing. It is the clinical management of a quantifiable, measurable gap between where your hormones are and where they need to be for your body to function as it should.
The hormones involved in a complete protocol are not exotic. A clinician who orders only one category of this panel — sex hormones only, or thyroid only — is not doing hormone optimization. They are doing hormone sampling.
The four axes of a complete protocol
Optimization assesses every axis, not one in isolation
| Axis | What it governs | Core markers |
|---|---|---|
| Sex hormones | Body composition, libido, bone density, mood, cognition | Testosterone (total + free), estradiol, progesterone, DHEA-S, SHBG |
| Thyroid | The metabolic governor — energy, fat metabolism, cognition, temperature | TSH, free T3, free T4, reverse T3, TPO + thyroglobulin antibodies |
| Adrenal / stress | Sex-hormone production, central fat, sleep quality | Cortisol (diurnal), DHEA-S |
| Metabolic | Insulin signaling and cardiovascular risk — bidirectional with hormones | Fasting insulin, HbA1c, glucose, CMP, lipids |
Men and Hormone Optimization: The Underdiagnosed Half
The cultural framing of hormone optimization as a women's issue has left an enormous gap in men's healthcare. Testosterone declines in men at approximately 1 percent per year after age 30. By age 45, a meaningful proportion of men have levels that would have been clinically notable at 30 — but because the decline is gradual, the symptoms accumulate slowly and are routinely attributed to stress, aging, or lifestyle.
The symptoms of male hypogonadism are not obscure. They are among the most common complaints in primary care: fatigue, reduced motivation, decreased muscle mass despite consistent training, increased central fat, reduced libido, diminished or absent morning erections, mood flattening, sleep disruption, and cognitive slowness. Each individually gets attributed to something else. In combination, the clinical picture is consistent and measurable.
The complete male hormone panel
Each marker changes the protocol — not one of them is optional
| Marker | Why it is ordered |
|---|---|
| Total + free testosterone | Free is the bioavailable fraction; the total alone can hide a deficiency |
| SHBG | High SHBG binds testosterone and reduces what the body can actually use |
| Estradiol | Men aromatize testosterone to estrogen; elevated estradiol mimics low T |
| LH + FSH | Distinguishes testicular (primary) from pituitary (secondary) origin |
| Prolactin | Elevated prolactin suppresses testosterone — an important differential |
| PSA + CBC | Baseline safety before therapy; testosterone affects hematocrit |
| Full thyroid panel | Hypothyroidism mimics low T and must be ruled out or co-treated |
| CMP, lipids, HbA1c, fasting insulin | Metabolic context that low T both causes and worsens |
Most labs define the normal total testosterone range as roughly 300 to 1,000 ng/dL. A 45-year-old man at 310 ng/dL is reported as normal, and his symptoms are attributed to lifestyle. The number clears the floor — but the floor was set by a population distribution, not by what that specific individual requires to function.
A number at the low end of the reference range in a symptomatic patient is not a reassurance. It is the beginning of a clinical conversation. I read testosterone in context — age, symptoms, free fraction, SHBG, and estradiol — never as a single value against a floor.
Women and Hormone Optimization: Beyond Menopause
The framing of female hormone optimization as a menopause issue misses the majority of the clinical population. Hormonal dysregulation in women begins, for many, in the late 20s and early 30s — triggered by stress, nutritional depletion, thyroid dysfunction, or the hormonal aftermath of pregnancy. By perimenopause, typically beginning in the early-to-mid 40s, the shifts become undeniable. But patients who arrive at perimenopause have often been symptomatic for a decade or more.
Perimenopause is not a single event. It is a 4-to-10-year transition characterized by erratic estrogen fluctuations, accelerating progesterone decline, and eventually testosterone reduction. The FSH-based marker most providers rely on is a late-stage indicator: a patient in early perimenopause with significant symptoms will often have a normal FSH because the pituitary is still compensating.
The complete female hormone panel
Ordered to the cycle and the symptom picture, not a single estradiol draw
| Marker | Why it is ordered |
|---|---|
| Estradiol | Day 3 if premenopausal; any time if peri- or postmenopausal |
| Progesterone | Day 21 if premenopausal — confirms ovulation and luteal adequacy |
| Total + free testosterone | Low testosterone in women drives lost libido, drive, and lean mass |
| DHEA-S + SHBG | Adrenal reserve and the binding that governs free hormone |
| LH + FSH | Stage the transition — but never the only markers |
| Full thyroid panel | TSH, free T3, free T4, reverse T3, TPO + thyroglobulin antibodies |
| Cortisol (diurnal) | Stress-axis load that suppresses sex hormones directly |
| CMP, lipids, HbA1c, fasting insulin, vitamin D | Metabolic context; low vitamin D mimics and worsens dysregulation |
Female testosterone is measured in the low nanogram range and the reference ranges are poorly standardized. Many labs flag low-normal levels as acceptable, and many clinicians do not discuss testosterone with female patients at all. The result is a large population of women with measurable low testosterone — losing libido, drive, and lean mass — told their hormones are fine because estrogen was the only sex hormone checked.
The Thyroid Problem That Neither Side Catches
Thyroid dysfunction is the most commonly missed hormonal diagnosis in both men and women — not because it is rare, but because the standard of care for thyroid testing is inadequate. TSH is a pituitary hormone: an indirect measure of what the brain is signaling, not what the thyroid is producing or what the cells are receiving. A normal TSH with low free T3 or elevated reverse T3 is a clinically significant pattern that most providers never see, because free T3 and reverse T3 are not in the standard panel.
The clinical picture of undertreated thyroid disease is consistent: fatigue sleep does not resolve, cold intolerance, weight that will not move despite an appropriate deficit, constipation, brain fog, depressive symptoms not responding to antidepressants, hair loss including the outer third of the eyebrows, elevated LDL with no dietary explanation, and dry skin.
A patient with a TSH of 2.8, a free T3 in the lower third of the range, and an elevated reverse T3 — with a symptomatic picture — is not a patient whose thyroid is fine. They are a patient whose thyroid deserves clinical attention. GoodLife Health orders the complete thyroid panel on every patient and interprets it in context, not in isolation.
How GoodLife Health Approaches Hormone Optimization
The intake is not a questionnaire that leads to a prescription. It is a structured clinical assessment.
- Baseline laboratory panel. Before any protocol is designed, Kristin orders the comprehensive panel appropriate to your presentation — sex hormones, full thyroid, adrenal markers, metabolic panel — drawn through a reference laboratory and reviewed directly by her, not summarized by an algorithm.
- Clinical interpretation, not reference-range matching. Results are read against your symptoms, age, history, medications, and goals. A result in the lower quartile of "normal" in a symptomatic patient is a finding, not a reassurance.
- Protocol design for the individual. For a man with low free testosterone, high SHBG, and subclinical hypothyroidism, the protocol addresses all three at once. For a perimenopausal woman with low progesterone, normal-low estradiol, and elevated reverse T3, it addresses the thyroid first.
- Titration and follow-up. Hormone therapy is not set-and-forget. It is monitored at defined intervals — typically 6 to 8 weeks after any change — to confirm response and adjust. This follow-up is part of the membership, not an additional billing event.
- Longitudinal care. A patient optimized at 45 is reassessed at 50, 55, and beyond. The protocol evolves with the patient. That is the definition of a clinical relationship — and the thing transaction-built platforms cannot provide.
The correct question is not "what do you prescribe?" It is "what do you measure, how often, and what is your titration logic when the first protocol does not work?"
The test of a real hormone program
What Separation Actually Looks Like
Hormone optimization across four delivery models
How GoodLife Health compares to the alternatives
| Dimension | GoodLife Health | Single-hormone platform | Concierge practice | Standard primary care |
|---|---|---|---|---|
| Panel depth | Full multi-axis: sex, thyroid, adrenal, metabolic | Single hormone + basic safety labs | Often comprehensive | TSH only; basic metabolic |
| Clinician | Named DNP, direct access | Often a PA/NP behind an intake form | Named MD, limited access | PCP, 8-minute visit |
| Protocol design | Multi-hormonal, individualized | Single hormone, standardized | Individualized | Reactive, not proactive |
| Titration included | Yes — follow-up labs in membership | Sometimes; often billed separately | Yes, at added visit cost | Rarely; referral out |
| Medication margin | Zero — you pay your pharmacy directly | Often marked up or bundled | Varies; often dispensed in-house | Not applicable |
| Monthly cost | $299/month (Tier 1) | $150-$400/month | $800-$2,500/month | Copays + deductible |
| Men and women | Both | Usually one only | Both | Both |
| Thyroid included | Full panel, every patient | Rarely | Often | TSH only unless referred |
What $299 Per Month Actually Buys
GoodLife Health operates on three membership tiers. Hormone optimization is Tier 1.
Membership tiers
Medication is always separate — GoodLife takes zero margin on any prescription
| Tier | Price | What it covers |
|---|---|---|
| Tier 0 — DPC Foundation | $179/month | Unlimited clinician messaging, primary care, lab review, care coordination |
| Tier 1 — DPC + Hormone Optimization | $299/month | All of Tier 0 plus the complete hormone protocol: baseline panel, protocol design, ongoing titration and follow-up labs, direct access to Kristin |
| Tier 2 — DPC + Hormone + Medical Weight Loss | $399/month | All of Tier 1 plus the clinically supervised GLP-1 protocol, full metabolic workup, and maintenance planning |
Medication is always separate. GoodLife Health does not dispense or compound medication and takes zero margin on any prescription. You pay your pharmacy directly at pharmacy prices. This is not a fine-print disclosure — it is the business model. The membership pays for the clinician. The pharmacy pays for the drug.
The average individual deductible on a US employer plan in 2026 runs about $1,800 per year; marketplace bronze plans routinely carry deductibles of $7,500 or more before coverage begins. GoodLife Health at $299 per month is $3,588 per year — less than most patients spend reaching their deductible, while also receiving unlimited clinician access, a complete hormone panel, and ongoing titration rather than a referral to an endocrinologist with a four-month wait.
Every compounded hormone platform makes money when you refill. Every concierge practice makes money on the retainer regardless of whether your protocol works. Every specialist makes money on the visit, not the outcome. GoodLife Health makes money when you stay a member — and you stay when your protocol works, your labs improve, and your symptoms resolve. That is not a marketing position. It is an incentive structure, and it is the only one in this market that is structurally on your side.
Why You Cannot Out-GLP-1 a Hormonal Imbalance
This is the single most underappreciated clinical reality in the weight-management space in 2026. GLP-1 medications are among the most effective pharmacological tools for weight reduction in the history of medicine — in controlled trial populations.
In real-world practice, a meaningful proportion of patients on appropriately dosed GLP-1 do not achieve comparable results. The most common clinical reason is undertreated hormonal dysregulation. Hypothyroidism reduces basal metabolic rate and fat oxidation — the drug reduces appetite while the thyroid slows everything the appetite reduction is meant to address. Low testosterone reduces lean mass and blunts insulin sensitivity. Estrogen dominance in perimenopause drives central adiposity and insulin resistance through mechanisms GLP-1 does not touch.
The clinical implication is direct: a complete metabolic and hormonal assessment before initiating GLP-1 is not a luxury. It is the difference between a protocol that works and one that works partially and expensively. GoodLife Health Tier 2 was designed around this reality — the hormonal assessment and the GLP-1 protocol are one clinical workflow, one clinician, one lab panel, one follow-up cadence.
Why Your Labs Are Normal and You Still Feel Terrible
Reference ranges for most hormones are built from population distributions, not from optimal function. The range typically represents the middle 95 percent of a reference population — so the bottom quartile of "normal" may be profoundly symptomatic for an individual who was previously functioning in the upper half and has declined without ever crossing the floor.
Three patterns behind "normal labs, real symptoms"
The ratio and the free fraction are the finding — not the single value
| Pattern | What looks normal | What is actually wrong |
|---|---|---|
| Free vs total testosterone | Total testosterone in range | High SHBG binds it; the bioavailable free fraction is low |
| TSH normal, free T3 low | TSH and T4 in range | T4 is converting to reverse T3, not active free T3 — functionally hypothyroid at the cell |
| Estradiol in range, progesterone low | Estradiol normal | Progesterone deficiency creates estrogen dominance — the ratio is the problem |
Kristin Makinajyan evaluates ratios, patterns, and clinical context — not individual values against a floor. That is what clinical interpretation means.
How to Evaluate Any Hormone Program
The hormone optimization market includes platforms serving men only, women only, and a smaller number serving both — most built around a single hormone and a single delivery mechanism. Five questions separate a clinical program from a transaction:
- What panel do you order before designing a protocol? If it does not include full thyroid and adrenal markers alongside sex hormones, it is incomplete.
- Who interprets my labs, and do I speak with them directly? The clinician who reads your labs should be the one who designs your protocol and answers your questions.
- What happens if my first protocol does not work? The answer should name specific actions — revisit labs, adjust dose, evaluate cofactors, change delivery — not "we'll figure it out."
- How does medication pricing work? A program that bundles medication into a fee or sells compounded hormones in-house has a financial interest in your refill volume worth understanding.
- Do you treat men and women? A program built around one gender's physiology often gives the other incomplete care.
Competitors: The Honest Comparison
- Midi Health — Women-focused telehealth for menopause and hormone care. Serves the perimenopausal patient well within scope. Does not serve men, does not typically include full thyroid panels as standard, and does not integrate GLP-1 or metabolic weight loss into one protocol.
- Allara Health — Women with PCOS and hormonal conditions. Clinically competent within a narrow scope; not a fit for the optimization buyer without a PCOS diagnosis. Men are out of scope.
- Hims (men's health) — Testosterone and men's health, transaction-oriented through asynchronous intake. Does not include comprehensive thyroid or adrenal panels as standard. No female patients; no integration with metabolic or weight management.
- BodyLogicMD / Parsley Health and similar functional-medicine practices — More comprehensive protocols at a higher price point ($400-$1,000+/month), often hybrid or in-person and geographically limited, with medication frequently dispensed in-house or through partner compounding pharmacies.
GoodLife Health: Tier 1 at $299 per month. Men and women. Full multi-axis panel. Named clinician, direct access. Zero medication margin. Integrated with GLP-1 and metabolic weight loss at Tier 2. Telehealth, available in all eligible states. The clinical relationship is the product — not a subscription to a drug-delivery service.
What to Expect in the First 90 Days
The first 90 days is a calibration period, not a results period. Setting that expectation is the most important thing a clinician can do.
A protocol that is not titrated after initial response is not being managed — it is being maintained at a starting dose indefinitely. Patients who are appropriately diagnosed, correctly dosed, and consistently monitored typically report meaningful improvement in energy, sleep, body composition, libido, and cognitive clarity by week 12. Some markers — thyroid in particular — take longer to fully normalize.
Frequently Asked Questions
What is the difference between hormone optimization and hormone replacement therapy?
Hormone replacement therapy typically refers to replacing hormones that have declined below a clinical threshold. Hormone optimization includes HRT but extends to a broader goal: assessing the full hormonal picture — sex hormones, thyroid, adrenal — and bringing each into the range where the individual patient functions optimally, not just above the clinical floor. The distinction matters because optimization begins earlier and covers more axes than traditional replacement therapy.
Does GoodLife Health treat both men and women for hormone optimization?
Yes. The protocol is designed for adults of any gender. Men receive the full male assessment including testosterone, estradiol, LH, FSH, prolactin, PSA, and complete thyroid. Women receive the full female assessment including estradiol, progesterone, testosterone, DHEA-S, SHBG, and complete thyroid with antibodies. The panel, protocol design, and titration logic are calibrated to each patient's specific hormonal profile — not to a gender category.
How long does it take to see results from hormone optimization?
Sleep and energy improvements typically emerge within 3-5 weeks of an appropriately designed protocol. Body-composition changes require 10-14 weeks to become measurable. Full thyroid optimization takes longer. The honest answer is 90 days to meaningful clinical improvement and 6 months to a fully calibrated, stable protocol.
What does GoodLife Health's hormone optimization membership cost?
Tier 1 is $299 per month. This covers the full clinical protocol: comprehensive baseline labs, protocol design, titration, follow-up labs, and unlimited clinician messaging with Kristin Makinajyan, DNP, FNP-BC. Medication is a separate cost paid at your pharmacy. GoodLife takes no margin on any prescription.
Can I do hormone optimization and GLP-1 therapy at the same time?
Not only can you — for many patients, you should. Undertreated hypothyroidism or testosterone deficiency reduces the effectiveness of GLP-1 therapy, and GLP-1 weight loss without adequate testosterone and protein support accelerates lean-mass loss. GoodLife Health Tier 2 manages both protocols simultaneously under the same clinician, against the same lab panel, with the same follow-up cadence.
Why do my labs show normal results when I still feel terrible?
The most common reason is that an incomplete panel was ordered: TSH without free T3, total testosterone without free testosterone and SHBG, estradiol without progesterone. Each number may clear the reference floor while the clinical picture — the ratios, the patterns, the free fractions — tells a different story. GoodLife Health orders the complete panel and interprets it in clinical context.
Is hormone optimization safe for both men and women?
Yes, when clinically supervised. The safety profile of testosterone replacement in appropriately screened men is well established. Estrogen and progesterone therapy in women has been extensively studied since the Women's Health Initiative, and current evidence supports its safety and benefit for most women under 60 who begin within 10 years of menopause onset. Thyroid optimization is among the most studied interventions in medicine. Safety requires appropriate baseline assessment, correct dosing, and monitoring — which is exactly why unsupervised hormone therapy carries real risk.
Related Reading
- GLP-1 and Hormone Optimization: Why You Need Both
- Why Your Labs Are Normal and You Still Feel Terrible
- Best Medical Weight Loss Programs: The Clinically Honest Guide for 2026
- What GoodLife Health Actually Costs: The Complete Pricing Guide
- Meet Kristin Makinajyan, DNP, FNP-BC
References
- Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2018. 10.1210/jc.2018-00229
- Stuenkel CA, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2015. 10.1210/jc.2015-2236
- Wierman ME, et al. Androgen Therapy in Women: A Reappraisal. Journal of Clinical Endocrinology and Metabolism. 2014. 10.1210/jc.2014-2260
- Garber JR, et al. Clinical Practice Guidelines for Hypothyroidism in Adults. Thyroid. 2012. 10.1089/thy.2012.0205
- Davis SR, et al. Testosterone in Women — The Clinical Significance. Lancet Diabetes and Endocrinology. 2015. 10.1016/S2213-8587(15)00284-300284-3)
- Traish AM. Testosterone and Weight Loss: The Evidence. Current Opinion in Endocrinology, Diabetes and Obesity. 2014. 10.1097/MED.0000000000000086
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022. 10.1056/NEJMoa2206038